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Antonio Ugalde and Núria Homedes
present in their article “Four words regarding
clinical trials: science/profit, risks/benefits” (1) a
series of arguments about the vicissitudes of
clinical trial development in Latin America. The
four words constitute two binomials, each term in
tension with its counterpart. The arguments of the
authors are of unquestionable weight and are
founded in unobjectionable information that
makes them difficult to contradict. The authors
focus on clinical trials conducted in Latin America,
but the article – fortunately – provides abundant
examples that also implicate the so-called central
countries in fabrications, concealments and ethical
transgressions of great magnitude in research
studies carried out in their own territories and on
their own citizens. The article could be of great
assistance in designing local antidotes to this
problem, as reflective and critical analyses of this
kind are only developed in certain small circles,
with some involvement from the area of bioethics,
very little from the health services field and almost
none from our universities. 
Science or profit
Clinical trials represent one part of the
scientific activity that aims at making new drugs
available to humans. The first, and maybe the most
obscure scientific activity, is that of the discovery
and/or the design of molecules that have
therapeutic purposes; the second activity is that of
demonstrating – using scientific methods – that this
therapeutic effect is real and that, in addition to
being effective these molecules are safe for the
desired purposes. This is the ferrying mechanism of
clinical trials: they make the passage from molecule
to drug viable. True scientific innovation stems
from the discovery and/or design of molecules,
while the testing of the qualities of these molecules
in people – clinical trials – involve methodological
procedures that use standardized and sophisticated
statistical tools (2 p. 63- 71). In this sense, the
development of clinical experimentation with
drugs cannot be considered in and of itself
pharmaceutical innovation, an idea which tends to
be coarsely and self-interestedly disseminated by
the transnational pharmaceutical industry. Another
concept connecting science and clinical trials refers
to the participation of different fields in scientific
activities: the biological disciplines (which could
be defined as medicine and physiopathology) and
the pharmaceutical disciplines. The overriding
question is whether knowledge of physio-
pathological mechanisms induces the discovery of
molecules capable of interfering in these
mechanisms, or if is the other way around, with the
chemistry of the molecules shedding new light on
the physiopathology. This issue would be
secondary if it were simply a reflection on the
origin of what stimulates of knowledge, but the
question is not innocent: in the framework of the
development of the pharmaceutical industry, the
chemistry of molecules "produces physio-
pathologies" categorized as diseases (2).
What is it that leads the chemistry of mol-
ecules to subject physiopathological knowledge?
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And then yet another subjection: that of chemistry
to the "methodology of clinical trials." The develop-
ment of trials within the pharmaceutical industry,
and with great financial stimuli, makes it so that
…clinical trials are not simply one more test in
the perfection of a drug, but in fact the center of
the matter, the point where the scientific,
medical and financial aspects intertwine in order
to determine what will earn the title of progress
and allow a lot of money to be made. (2)
The pharmaceutical industry itself states
that its activity is an industry, and obscenely
refers to itself as an industry without chimneys
(3), thus associating itself as if in passing with
tourism, the business activity usually referred to
in this way. This industry represents for the
transnational pharmaceutical industries an
essential base from which to expand profits, far
from providing authentic pharmaceutical
innovations to the world. The issue of innovation
is thoroughly analyzed by M. Angell (4), who
states that, in the five-year period of 1998-2002,
the Food and drug Administration (FdA)
approved no more than twelve innovative drugs
per year, which amounts to only 14% of the total
licenses granted (4 p.76-77). 
But where do the substantial profits for
the pharma industry come from if there is so little
innovation? The answer is found putting a new face
on molecules of known drugs, that is to say,
modifying them only slightly: these are the "me-
too" drugs. And in this way the industry without
chimneys puts its machinery in motion to justify
that the new drugs are no less effective than the
previous drugs, or more effective than placebos. 
The displacement of clinical research
development from university centers to for-profit
clinical research organizations – the so-called
Contract Research organizations (CRo) – fostered
by the industry itself to guarantee total control
over the design and execution of the trials and
above all of their results, is the background that
explains the frauds and data falsifying that Ugalde
and Homedes comment upon: “It is no longer the
researchers but rather the sponsors who control
the clinical trials” (4 p.123).
Clinical trials are a particular type of
scientific activity, for the reasons mentioned above
and because they convene a particular type of
researcher, mainly pragmatic doctors.  These are
strange creatures within the canons of traditional
scientific research because they do not participate
in the identification and definition of the research
question, in the formulation of the hypothesis, in
the design of study protocol, in the analysis of the
data collected; and they have no knowledge of the
study’s results. Ugalde and Homedes called them
maquiladores, a sort of subject/object of an
assembly line.
In the last five years in Argentina,
criticism of the way clinical trials have been
conducted from the a bioethics and human rights
point of view has increased, particularly due to
the events that took place in studies with
vaccines in children (5) that were made public
(6), and due to the subsequent sanctions imposed
on the principal researchers and the sponsoring
laboratory by the national regulatory body
(ANMAT) and ratified judicially (7). Even so, the
transnational pharmaceutical industry still
imposes industrial-business logic in clinical
research as a source of foreign capital for the
country, an opportunity for the transference of
technology and way of establishing investments.
As Ugalde and Homedes correctly assert, “the
governments of the region have accepted the
industry’s rationalization” (1). In Argentina, the
transnational pharmaceutical laboratories
propose improving the balance of trade by
bringing more clinical trials into the country (8),
and from the economy and business sectors
within the executive power mechanisms are
created to foster such proposals (9). The previous
comment regarding the smallness of the spaces
open to critical reflection regarding these issues is
thus made evident, as they are unable to
introduce such issues into the political agenda of
the government.
risk or benefit
The previous commentary does not
serve as impediment for considering the
randomized clinical trial to be a (or the) paradigm
within the medical research. The most wide-
spread precautionary measures regarding clinical
trials address methodological concerns deriving
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from the existence of factors that threaten the
quality of the information acquired. Ugalde and
Homedes go even further to detect mistakes that
escape purely methodological considerations. As
a complement to the observations of these
authors and, fortunately, removed from such
lukewarm methodological objections, it is
possible to find within the core of medical
empiricism excellent analyses that grant a
comprehensive view of limits and risks in the
assessment of randomized and controlled clinical
studies. A highly circulated publication among
cardiology practitioners of Argentina regarding
evidence in cardiology dedicates an entire
chapter to the detailed analysis of what is true
and what is false in medical publications (10).
Using as a basis a "classification of falsehoods" it
takes on considerations of fraud, manipulation
and concealment of information, physio-
patological truths and clinical falsehoods, etc.
Regretfully, pragmatic doctors tend to constrain
themselves to a methodological trust in a
statistically significant p-value of less than 0.05 or
0.01 as criterion of truth, and to the opinion of
experts from well-regarded journals (10).
And what of the benefits of clinical
trials? This is the second term, the other half of
the question asked by the second binomial. on
this subject I prefer to reiterate the conclusions of
Ugalde and Homedes: “In the dichotomies
science/profit and risk/benefit, clinical trials
presently represent more profit than science, and,
for the poor participants, imply more risks than
benefits" (1).
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